Dihydroergotoxine

• Catalog No.: DB01287
• CAS Number: 11032-41-0
• M. F.: C34H41N5O8S
• M. W.: 679.78304

SYNONYMS

• IUPAC name: (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid
• IUPAC Traditional name: (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide mesylate

DATABASE IDS

• PubChem SID: 46505136
• PubChem CID: 6420006
• CAS Number: 11032-41-0

DETAILS

Description (English)

• Drug Groups: approved
• Description: Dihydroergotoxine is a cerebral vasodilator. Dihydroergotoxine is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.
• Indication: For potential use in the treatment of Alzheimer's disease.
• Pharmacology: The drug may compensate for neurotransmitter deficits and can in different circumstances, compensate for hyperactivity in the same neurotransmitter pathways. The drug can counteract and prevent disturbances between monoaminergic and other transmitter systems in the CNS.